Vaxart Inc. Stock
Vaxart Inc. Stock
Vaxart Inc. gained 0.140% compared to yesterday.
For the coming years our community has positive and negative things to say abot the Vaxart Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Vaxart Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vaxart Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vaxart Inc. | 0.140% | -0.285% | -15.152% | -55.731% | -58.457% | -73.807% | -95.410% |
| Larimar Therapeutics Inc. | 1.190% | 6.623% | 8.784% | -48.889% | -13.441% | -6.395% | -83.088% |
| Achieve Life Sciences Inc. | 1.410% | -0.764% | -3.470% | -7.262% | 9.257% | 62.971% | -38.661% |
| aTyr Pharma Inc | -1.650% | 13.084% | 6.140% | -80.732% | -82.910% | -69.460% | -81.777% |
Comments
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for AVIR provided by MarketBeat
News
Vaxart Revenue Jumps 520% in Fiscal Q2
Vaxart (OTC:VXRT), a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a
